Numerous studies have revealed that mutant p53 can lose their tumor-suppressive function and obtain dominant−negative activities that are independent of wild−type p53, which may confer them oncogenic functions to participate in cancer development (15, 16). This evidence concerns the gene TP53 and cancer.